Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating DSM-IV depression with atypical features.

Jonathan W Stewart1, Michael E Thase

  • 1Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, USA.

The Journal of Clinical Psychiatry
|May 4, 2007
PubMed
Summary

Atypical depression treatment primarily involves monoamine oxidase inhibitors (MAOIs) like phenelzine, which show superior efficacy. Newer agents and therapies are also discussed for managing this specific depression subtype.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Effect of age on the response to serotonergic and noradrenergic antidepressants: A systematic review, meta-regression and individual participant data pooled analysis" [J. Psychiatr. Res. 183 (2025) 133-143 doi. 10.1016/j.jpsychires.2025.02.013].

Journal of psychiatric research·2025
Same author

Effect of age on the response to serotonergic and noradrenergic antidepressants: A systematic review, meta-regression and individual participant data pooled analysis.

Journal of psychiatric research·2025
Same author

Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials.

Brain communications·2022
Same author

A randomized, controlled trial assessing the acute efficacy of triple chronotherapy in unipolar depression.

Journal of affective disorders·2021
Same author

Gray matter reorganization underpinnings of antidepressant treatment of persistent depressive disorder.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2021
Same author

Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children.

Focus (American Psychiatric Publishing)·2020

Area of Science:

  • Psychiatry
  • Clinical Psychology

Background:

  • Atypical depression presents with mood reactivity and vegetative symptoms.
  • It demonstrates a distinct treatment response, favoring MAOIs over TCAs.

Purpose of the Study:

  • To review current treatments for DSM-IV depression with atypical features.
  • To focus on findings from placebo-controlled trials.

Main Methods:

  • Review of placebo-controlled trials for atypical depression treatments.
  • Discussion of various therapeutic agents including MAOIs, TCAs, and SSRIs.

Main Results:

  • Phenelzine (an MAOI) exhibits the highest efficacy in treating atypical depression.
  • Efficacy of newer agents compared to MAOIs and TCAs remains uncertain.

Related Experiment Videos

Conclusions:

  • Phenelzine is a highly effective treatment for atypical depression.
  • A comprehensive review of available treatments, including newer agents and therapies, is presented.